Travera Billing Policy

1. Our billing promise

Travera confirms the ordered panel, total price, included physician review and collection charges, and applicable policy version before testing and records your acceptance. We collect no advance payments or deposits and issue no invoice before the applicable report is released as described in section 5. If testing is not approved, no testing, associated MDI physician review, or Travera-arranged collection charge is passed to the patient. The combined patient-identity and results acknowledgment is not acceptance of a testing price or authorization to incur charges. Scope-and-price acceptance and any recollection decision remain separate; the report cover letter does not change accepted billing terms.

No result = no bill. For Nova Select, Nova Select Extended Panel, and RapidSelection, “no result” means fewer than three unique ordered drugs with reportable results: zero, one, or two means you owe nothing for the panel, associated physician review, or Travera-arranged collection. Three or more means the full agreed price applies, even if some drugs cannot be reported. There is no proration or tiered pricing. Each panel is assessed separately; results from separate orders are not pooled. The basic Nova Select panel includes five commonly used immunotherapy drugs for $4,000 total. Nova Select Extended Panel includes those five drugs plus seven additional drugs, for twelve drugs and $6,000 total ($2,000 more). Each total includes MDI physician eligibility and ordering review and blood collection, shown as separate invoice line items within that total, not as additional charges. For the extended panel, three or more reportable drugs from the twelve ordered drugs makes the full $6,000 payable, even if none of the seven additional drugs is reportable; zero to two means $0. If the MDI clinician approves the extended panel, you may choose the basic or extended panel before testing; we confirm the corresponding order and record your panel and price acceptance. Other services have their own agreed prices. The included physician service covers eligibility and ordering; a routine follow-up consultation to discuss results is not included.

2. What counts as reportable

The Laboratory Director determines reportability under Travera’s validated procedures and quality-control requirements. A reportable result can be included in a final patient report; billing personnel do not decide reportability.

A valid result showing little or no measurable response is reportable. Specimen limitations, insufficient viable cells, technical or quality-control failure, or other laboratory limitations may prevent a valid result. Each drug counts only once toward the three-drug threshold.

3. Nova Fit and Immune Profiling

Nova Fit and Immune Profiling are product-level tests: the full agreed price is billable when quality-control requirements are met and a final report is issued and released as described in section 5. Otherwise, there is no charge for that test or its associated physician review and Travera-arranged collection. The three-drug threshold does not apply.

4. Incomplete drug panels and complimentary recollection of blood

For Nova Select and Nova Select Extended Panel, any missing ordered drug result qualifies for one complimentary recollection and laboratory attempt when scientifically and clinically appropriate, regardless of the initial reportable-drug count. We promptly release available results without waiting for your decision or payment.

The complimentary attempt includes Travera’s standard kit, collection arrangements, shipping, and testing; for blood-based tests, it includes the standard blood draw. There is no additional charge for this repeat collection or laboratory attempt. “Complimentary” does not waive the original agreed price if the combined results meet the three-drug billing threshold. Before you choose recollection, we explain your current reportable-drug count, current amount owed, and the total that will become payable if the threshold is reached, and record your acceptance. RapidSelection requires an appropriate tissue or malignant-fluid specimen, subject to availability and the treating clinician’s assessment. This policy neither requires nor authorizes a new biopsy or other invasive procedure.

Independently incurred third-party procedure charges are addressed under section 7.

Elect recollection within five business days after the initial report is released as described in section 5. Recollection generally must occur within 14 calendar days of that date and, when clinically applicable, before a material treatment change. The Laboratory Director may rule it inappropriate because of treatment timing, biological limitations, or other clinical or laboratory considerations. Additional reportable results are not guaranteed.

If you decline, do not respond within five business days, or recollection is unavailable or not completed in time, billing follows the initial report: the full agreed total for three or more reportable drugs; nothing owed, including associated physician review and Travera-arranged collection fees, for zero to two. Travera will notify you of any approved extension and invoice hold.

For a completed complimentary attempt, invoicing waits until its report is released as described in section 5. Billing counts unique ordered drugs with valid reportable results across both attempts: the full agreed total for three or more; nothing owed, including associated physician review and Travera-arranged collection fees, for zero to two. Each drug counts once; withdrawn or invalid results do not count. Charges for the original service and its complimentary repeat attempt never exceed the agreed total. For example, two initial reportable drug results plus a result for one additional ordered drug from the repeat attempt make standard Nova Select billable at $4,000 total. For Nova Select Extended Panel, the same two-plus-one example makes $6,000 total payable. If the repeat adds no new reportable drug, the total remains $0. If the initial attempt already produced three or more reportable drug results, additional results do not increase or reduce the agreed price.

5. Report dates, invoices, and payment deadlines

For requests initiated through MDI, the report-release date is the date the applicable report is available in the patient portal and accessible to the ordering clinician, and notice of its availability has been sent to the patient or financially responsible party. If these occur on different dates, the later date applies. For other physician orders, the report-release date is the later of the date the report is sent to the ordering clinician and the date notice is sent to the patient or financially responsible party. We communicate applicable payment and recollection deadlines. Opening a message, viewing the report, or a clinician reviewing or interpreting it does not reset the date. Contact Travera promptly if you cannot access your report or need a copy. Billing notices and disclosures are limited to information legally permitted for payment or otherwise authorized. Being financially responsible does not itself authorize access to the patient’s report or full medical record. We honor applicable confidential-communication requests. An unpaid testing balance does not prevent the patient from exercising HIPAA rights to access completed reports and other covered records.

Payment is due 30 calendar days after the applicable report-release date, unless an approved payment arrangement provides otherwise. The initial report-release date applies unless a complimentary repeat attempt is completed. Waiting for the five-business-day recollection decision does not restart the payment period. Payment is based on reportability and release, not on a treating oncologist’s receipt or interpretation or a results consultation.

A completed complimentary repeat attempt starts a new 30-calendar-day payment period when its report is released as described in section 5. No payment is due during an approved invoice hold. If an extension ends without a completed attempt after the initial payment period, Travera will arrange a payment date without treating the invoice as overdue during the hold.

No invoice is issued for zero to two reportable drugs. Physician review and Travera-arranged collection fees are also waived, including when you decline or do not respond to the recollection offer. For a completed repeat attempt, this rule applies to the combined count of unique ordered reportable drugs.

6. Corrections and refunds

If a corrected report invalidates a result, we reassess billing. For Nova Select, Nova Select Extended Panel, and RapidSelection, fewer than three remaining unique ordered reportable drugs cancels the entire agreed charge, including associated physician review and Travera-arranged collection, or requires a full refund of those amounts if paid. Three or more leaves the full agreed total due, without a per-drug discount. For Nova Fit and Immune Profiling, no remaining reportable product-level result means cancellation or a full refund of the test and its associated physician review and Travera-arranged collection charges.

We issue required credits or refunds within 10 business days after the corrected report is released as described in section 5, using the original payment method where available.

7. Limits and separately disclosed charges

A valid result is not nonreportable merely because it shows little or no response, is unfavorable, unused, unexpected, or less useful than anticipated. Treatment changes after collection or delays beyond estimated turnaround do not alone entitle you to a refund under this policy. Nonwaivable legal rights remain unaffected.

Only one complimentary recollection and laboratory attempt is included. Any further testing, collection, or optional service requires separate advance disclosure and agreement; it is not an automatic charge under the original order. The included MDI physician eligibility and ordering review and blood collection are not extra charges above the $4,000 basic Nova Select total or the $6,000 Nova Select Extended Panel total. No charge billed or passed through by Travera for a nonbillable panel, including its associated physician review or Travera-arranged collection, may defeat the no-bill promise. Independently arranged services billed directly by an unrelated provider, such as a separate biopsy or treatment, are outside Travera’s bill and this policy; they are not the included MDI review or Travera-arranged blood collection. Travera collects no advance payment for services under this policy.

8. Payment arrangements and policy version

This policy covers direct-pay testing; Travera does not currently accept medical insurance. Payment plans and financial assistance may be available on request under separate terms, with no payment before the applicable report is released as described in section 5. This policy creates no subscription or automatic repeat-test charge.

This policy forms part of Travera’s Terms of Use and Testing Services. The version provided when you accept the scope and price governs your order; later changes are not retroactive. Your financial responsibility cannot exceed the amount disclosed and accepted before testing without your agreement.

9. Questions

Contact Travera at info@travera.com or 781-874-0808 for billing questions, recollection requests, or payment-arrangement assistance.